Breaking Down SG&A Expenses: Johnson & Johnson vs Alnylam Pharmaceuticals, Inc.

A Tale of Two Companies: SG&A Expenses Over Time

In the world of pharmaceuticals, understanding the financial dynamics of industry giants like Johnson & Johnson and innovative players such as Alnylam Pharmaceuticals, Inc. is crucial. Over the past decade, from 2014 to 2023, these companies have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses.

Johnson & Johnson, a stalwart in the industry, consistently reported SG&A expenses around $20 billion annually, with a slight dip in 2022. This stability reflects their established market presence and operational efficiency. In contrast, Alnylam Pharmaceuticals, a pioneer in RNA interference therapeutics, exhibited a remarkable growth trajectory. Their SG&A expenses surged from approximately $45 million in 2014 to nearly $800 million in 2023, highlighting their aggressive expansion and investment in market penetration.

This comparison underscores the diverse strategies employed by established and emerging pharmaceutical companies in navigating the competitive landscape.